Gene Therapy Preclinical Licensing Benchmarks
Deal economics across 38 transactions with 26 disclosed upfront payments. Primary-source-verified from SEC EDGAR, FTC filings, and direct research.
Median Upfront
$84M
26 deals with terms
Median Total Value
$1.1B
Upfront + milestones
Royalty Range
5.3%--12%
Average low--high
Deal Count
38
2020--2026
The median upfront payment for preclinical gene therapy licensing deals is $84M, based on 26 deals with disclosed terms from 2020--2026. Total deal values (including milestones) reach a median of $1.1B. Royalty rates typically range from 5.3% to 12%. All data is primary-source-verified from SEC EDGAR, FTC pre-merger filings, and company press releases.
Representative Transactions
| Licensor | Licensee | Year | Upfront | Total Value |
|---|---|---|---|---|
| Verve Therapeutics | Eli Lilly | 2026 | $1.3B | $1.3B |
| Verve Therapeutics | Eli Lilly | 2025 | $598M | $2.5B |
| Verve Therapeutics | Eli Lilly | 2022 | $237.5M | -- |
Showing 3 of 26 deals with disclosed terms. Full comp set available in the report.
Full gene-therapy Preclinical Comp Set
Get the complete analysis -- 26 deals with upfronts, milestones, royalties, and term structures.
Primary-source-verified from SEC EDGAR, FTC filings, and direct research
Run Your Own Analysis
Get a customized deal estimate for your specific gene therapy asset with our proprietary calculator.
Start CalculatingMethodology
This analysis draws from the Ambrosia Ventures proprietary deal database (1,600+ verified biopharma transactions, 2020--2026). All deal terms are primary-source-verified from SEC EDGAR (10-K, 10-Q, 8-K filings), FTC pre-merger notifications, FDA Orange Book, and company press releases. No secondary-source or scraped data is included. Medians are calculated from deals with disclosed financial terms only.